Phase II trial of modified FOLFIRINOX (irinotecan plus oxaliplatin and 5-fluorouracil/leucovorin) in patients with untreated metastatic pancreatic cancer
Phase 2
- Conditions
- untreated metastatic pancreatic cancer
- Registration Number
- JPRN-UMIN000013301
- Lead Sponsor
- Cancer Institute Hospital
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up continuing
- Sex
- All
- Target Recruitment
- 65
Inclusion Criteria
Not provided
Exclusion Criteria
Prior radiotherapy or chemotherapy Homotype of UGT1A1 genotype including *28/*28, *6/*6 and*6/*28 Evident pleural effusion, ascites, pericardial effusion or peritoneal metastasis on CT before enrollment Pulmonary fibrosis or interstitial pneumonia Watery stool within 3 days before enrollment Uncontrolled diabetes mellitus Any serious complication
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method